Table 2.
Baseline characteristics and outcomes of patients by GA categories
| GA ≤ 15.5% (n = 609) | GA > 15.5% (n = 412) | P value | |
|---|---|---|---|
| Male, m (%) | 465 (76.4%) | 287 (69.7%) | 0.017 |
| Age, y | 58.4 ± 10.0 | 63.0 ± 10.1 | 0.000 |
| BMI, kg/m2 | 26.0 ± 3.3 | 25.6 ± 3.1 | 0.126 |
| Medical history, n, (%) | |||
| Diabetes mellitus | 73 (12.0%) | 287 (69.7%) | 0.000 |
| Hypertension | 386 (63.4%) | 282 (68.4%) | 0.095 |
| Previous stroke | 62 (10.2%) | 51 (12.4%) | 0.272 |
| Previous myocardial infarction | 40 (6.6%) | 37 (9.0%) | 0.152 |
| Previous CABG | 2 (0.3%) | 6 (1.5%) | 0.067 |
| Previous PCI | 50 (8.2%) | 26 (6.3%) | 0.257 |
| Presentations of ACS | 0.319 | ||
| Unstable angina | 555 (91.1%) | 372 (90.3%) | |
| Non-STEMI | 23 (3.8%) | 23 (5.6%) | |
| STEMI | 31 (5.1%) | 17 (4.1%) | |
| Current or previous smoking, n (%) | 339 (55.7%) | 218 (52.9%) | 0.386 |
| Baseline laboratory evaluation | |||
| PLT, × 109/L | 220.8 ± 56.6 | 212.0 ± 60.2 | 0.019 |
| TC, mmol/L | 3.9 ± 1.0 | 3.9 ± 0.9 | 0.342 |
| LDL-C, mmol/L | 2.3 ± 0.8 | 2.2 ± 0.7 | 0.356 |
| HDL-C, mmol/L | 1.1 ± 0.2 | 1.1 ± 0.3 | 0.875 |
| TGs, mmol/L | 1.6 ± 0.9 | 1.5 ± 1.0 | 0.451 |
| Creatinine, μmol/L | 71.0 ± 14.4 | 70.7 ± 17.2 | 0.734 |
| Glucose indices | |||
| Fasting glucose, mmol/L | 5.4 ± 1.6 | 7.5 ± 2.4 | 0.000 |
| HbA1c, % | 5.9 ± 0.6 | 7.4 ± 1.4 | 0.000 |
| HOMA-IR | 2.1 (1.6–3.1) | 3.3 (1.9–4.9) | 0.000 |
| Antiplatelet responsiveness to clopidogrel | |||
| Responders to clopidogrel | 459 (75.4%) | 273 (66.3%) | 0.002 |
| ADPi | 45.4 ± 25.4 | 39.7 ± 23.8 | 0.000 |
| MAADP | 35.2 ± 14.5 | 39.0 ± 13.9 | 0.000 |
BMI body mass index, CABG coronary artery bypass graft, PCI percutaneous coronary intervention, non-STEMI non-ST-segment elevation myocardial infarction, STEMI ST-segment elevation myocardial infarction, PLT platelet count, TC total cholesterol, LDL-C low-density lipoprotein-cholesterol, HDL-C high-density lipoprotein-cholesterol, TGs triglycerides, HbA1c hemoglobin A1c, HOMA-IR homeostatic model assessment for insulin resistance, ADPi ADP-induced platelet inhibition rate, MAADP the maximum amplitude of ADP-induced platelet-fibrin clot strength